Awakn Life Sciences

Awakn Life Sciences Corp (NEO:AWKN) announced that it has signed a global licensing agreement with private pharmaceutical technology firm LTS Lohmann Therapie-Systeme AG for its proprietary S-ketamine formulation.  The biotechnology company said it would have exclusive use of LTS' proprietary S-ketamine formulation, administered sublingually via an oral thin film, for use in the treatment of addiction, anxiety and eating disorders. » Mehr auf proactiveinvestors.com

Conference hosted by M-Vest, Awakn to present on Thursday, June 22nd at 9:00 A.M. ET Toronto, Ontario--(Newsfile Corp. - June 19, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (the "Company"), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce that Awakn CEO, Anthony Tennyson has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Thursday, June 22nd at 9:00 A.M. » Mehr auf newsfilecorp.com

Awakn Life Sciences Corp (NEO:AWKN), a biotechnology company developing psychedelic therapies to treat addiction with a near-term focus on alcohol use disorder (AUD), is at an ideal entry point for investors given the company's de-risked ketamine Phase 3 trial for AUD in the UK as well as good momentum in its clinics, according to analysts at Stifel GMP.   In a note to clients, the analysts wrote that Awakn has progressed on multiple fronts, such as securing a differentiated partnership with the UK government to conduct its Phase 3 pivotal trial, Project Kestrel, for ketamine for severe AUD across seven NHS sites. » Mehr auf proactiveinvestors.ca